Our results suggest TGT parameters measured using the ST Genesia® platform may represent a suitable tool to monitor the hemostatic status of patients requiring a closer follow-up and a tailored therapeutic adjustment, overcoming the limitations of FVIII activity laboratory tests in clinical practice, and its application may be extended to other types of hemophilia or bleeding disorders. This evidence concerns the gene F8 and hemorrhagic disease.